FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229069942> ?p ?o ?g. }

• W4229069942 endingPage "1695" @default.
• W4229069942 startingPage "1685" @default.
• W4229069942 abstract "Several chemoimmunotherapy and targeted treatment regimens are approved as front-line therapies in chronic lymphocytic leukemia. We estimated for the 10-year cost-effectiveness of these treatment regimens and the economic burden of following the estimated risk-stratified 21 040 patients with chronic lymphocytic leukemia diagnosed in 2020 for 10 years.A Markov model with 7 exclusive health states was specified over a 10-year time horizon. Treatment effectiveness inputs were obtained from a novel network meta-analysis on the progression-free survival, overall survival curves, and time to next treatment. Costs and utilities inputs were included for each health state for each treatment and discounted at 3.0%/year. Life-years (LYs) and quality-adjusted LYs (QALYs) for each treatment were determined. Using the lowest cost regimen as reference, the incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) were estimated. The 10-year per-patient cost was determined by risk status and by initial treatment.Venetoclax-plus-obinutuzumab was the lowest cost regimen, hence the reference. Superior in effectiveness to all chemoimmunotherapies, it was cost saving. With the highest effectiveness gains at 6.26 LYs and 5.01 QALYs and despite being the most expensive regimen ($1 298 638 per patient), acalabrutinib-plus-obinutuzumab yielded the best ICER ($409 343/LY gained) and ICUR ($501 236/QALY gained). The remaining ICERs of targeted therapies ranged from $512 101/LY gained to $793 236/LY gained and the ICURs from $579 737/QALY gained to $869 300/QALY gained. The 10-year postdiagnosis low/high (venetoclax-plus-obinutuzumab/acalabrutinib-plus-obinutuzumab) economic burden ranges were $42 690 to $98 665 for low-risk, $141 339 to $326 660 for intermediate-risk, and $273 650 to $632 453 for high-risk patients.Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost. The targeted therapies achieve greater benefits at higher cost." @default.
• W4229069942 created "2022-05-08" @default.
• W4229069942 creator A5002479254 @default.
• W4229069942 creator A5022744383 @default.
• W4229069942 creator A5031828516 @default.
• W4229069942 creator A5049387929 @default.
• W4229069942 creator A5073861459 @default.
• W4229069942 creator A5085732144 @default.
• W4229069942 date "2022-10-01" @default.
• W4229069942 modified "2023-09-26" @default.
• W4229069942 title "Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia" @default.
• W4229069942 cites W1982967337 @default.
• W4229069942 cites W2016973656 @default.
• W4229069942 cites W2017628547 @default.
• W4229069942 cites W2022554071 @default.
• W4229069942 cites W2058056848 @default.
• W4229069942 cites W2059573268 @default.
• W4229069942 cites W2066564017 @default.
• W4229069942 cites W2095745169 @default.
• W4229069942 cites W2116835043 @default.
• W4229069942 cites W2117419474 @default.
• W4229069942 cites W2120319857 @default.
• W4229069942 cites W2124575836 @default.
• W4229069942 cites W2124847703 @default.
• W4229069942 cites W2146809992 @default.
• W4229069942 cites W2222788183 @default.
• W4229069942 cites W2233614027 @default.
• W4229069942 cites W2291155501 @default.
• W4229069942 cites W2294046808 @default.
• W4229069942 cites W2553911513 @default.
• W4229069942 cites W2559419065 @default.
• W4229069942 cites W2610097533 @default.
• W4229069942 cites W2725087275 @default.
• W4229069942 cites W2766509541 @default.
• W4229069942 cites W2770940163 @default.
• W4229069942 cites W2771732863 @default.
• W4229069942 cites W2788803761 @default.
• W4229069942 cites W2791345134 @default.
• W4229069942 cites W2889905810 @default.
• W4229069942 cites W2894684271 @default.
• W4229069942 cites W2902484351 @default.
• W4229069942 cites W2902590192 @default.
• W4229069942 cites W2902706178 @default.
• W4229069942 cites W2915408431 @default.
• W4229069942 cites W2948436219 @default.
• W4229069942 cites W2954017403 @default.
• W4229069942 cites W2963774393 @default.
• W4229069942 cites W2966190920 @default.
• W4229069942 cites W2970731184 @default.
• W4229069942 cites W2977253903 @default.
• W4229069942 cites W2990717807 @default.
• W4229069942 cites W2991188015 @default.
• W4229069942 cites W3012263096 @default.
• W4229069942 cites W3013074397 @default.
• W4229069942 cites W3016538158 @default.
• W4229069942 cites W3027791591 @default.
• W4229069942 cites W3045571650 @default.
• W4229069942 cites W3119005666 @default.
• W4229069942 cites W3175679928 @default.
• W4229069942 doi "https://doi.org/10.1016/j.jval.2022.04.001" @default.
• W4229069942 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35537984" @default.
• W4229069942 hasPublicationYear "2022" @default.
• W4229069942 type Work @default.
• W4229069942 citedByCount "3" @default.
• W4229069942 countsByYear W42290699422023 @default.
• W4229069942 crossrefType "journal-article" @default.
• W4229069942 hasAuthorship W4229069942A5002479254 @default.
• W4229069942 hasAuthorship W4229069942A5022744383 @default.
• W4229069942 hasAuthorship W4229069942A5031828516 @default.
• W4229069942 hasAuthorship W4229069942A5049387929 @default.
• W4229069942 hasAuthorship W4229069942A5073861459 @default.
• W4229069942 hasAuthorship W4229069942A5085732144 @default.
• W4229069942 hasConcept C112930515 @default.
• W4229069942 hasConcept C126322002 @default.
• W4229069942 hasConcept C143998085 @default.
• W4229069942 hasConcept C2777607594 @default.
• W4229069942 hasConcept C2777938653 @default.
• W4229069942 hasConcept C2778461978 @default.
• W4229069942 hasConcept C2780790343 @default.
• W4229069942 hasConcept C2781413609 @default.
• W4229069942 hasConcept C3019080777 @default.
• W4229069942 hasConcept C515549039 @default.
• W4229069942 hasConcept C64332521 @default.
• W4229069942 hasConcept C71924100 @default.
• W4229069942 hasConceptScore W4229069942C112930515 @default.
• W4229069942 hasConceptScore W4229069942C126322002 @default.
• W4229069942 hasConceptScore W4229069942C143998085 @default.
• W4229069942 hasConceptScore W4229069942C2777607594 @default.
• W4229069942 hasConceptScore W4229069942C2777938653 @default.
• W4229069942 hasConceptScore W4229069942C2778461978 @default.
• W4229069942 hasConceptScore W4229069942C2780790343 @default.
• W4229069942 hasConceptScore W4229069942C2781413609 @default.
• W4229069942 hasConceptScore W4229069942C3019080777 @default.
• W4229069942 hasConceptScore W4229069942C515549039 @default.
• W4229069942 hasConceptScore W4229069942C64332521 @default.
• W4229069942 hasConceptScore W4229069942C71924100 @default.
• W4229069942 hasIssue "10" @default.
• W4229069942 hasLocation W42290699421 @default.

• next